BioNTech SE will announce its financial results for the fourth quarter and full year of 2024 on March 10, 2025, followed by a conference call and webcast at 8:00 a.m. EDT. Interested parties can ...
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of ...
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association ...
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Penn sued BioNTech in August ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results